Rugo HS, Cescon DW, Robson ME, Im SA, et al. KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy. Clin Cancer Res 2025 Dec 17. doi: 10.1158/1078-0432.CCR-25-1818.
PMID: 41405563